Identification of factors impairing exercise capacity after severe COVID-19 pulmonary infection: a 3-month follow-up of prospective COVuability cohort

Bruno Ribeiro Baptista1†, Thomas d’Humières1,2†, Frédéric Schlemmer1,3, Inès Bendib1,2,4, Grégoire Justeau1, Lara Al-Assaad2, Mouna Hachem1,3, Rebecca Codi1,2, Benjamin Bardel2, Laure Abou Chakra2, Thibaut Belmondo5, Etienne Audureau6,7, Sophie Hue1,5, Armand Mekontso-Dessap1,4, Geneviève Derumeaux1,2 and Laurent Boyer1,2*

Abstract

Background: Patient hospitalized for coronavirus disease 2019 (COVID-19) pulmonary infection can have sequelae such as impaired exercise capacity. We aimed to determine the frequency of long-term exercise capacity limitation in survivors of severe COVID-19 pulmonary infection and the factors associated with this limitation.

Methods: Patients with severe COVID-19 pulmonary infection were enrolled 3 months after hospital discharge in COVuability, a prospective cohort. They underwent cardiopulmonary exercise testing, pulmonary function test, echocardiography, and skeletal muscle mass evaluation.

Results: Among 105 patients included, 35% had a reduced exercise capacity (VO2peak < 80% of predicted). Compared to patients with a normal exercise capacity, patients with reduced exercise capacity were more often men (89.2% vs. 67.6%, p = 0.015), with diabetes (45.9% vs. 17.6%, p = 0.002) and renal dysfunction (21.6% vs. 17.6%, p = 0.006), but did not differ in terms of initial acute disease severity. An altered exercise capacity was associated with an impaired respiratory function as assessed by a decrease in forced vital capacity (p < 0.0001), FEV1 (p < 0.0001), total lung capacity (p < 0.0001) and DLCO (p = 0.015). Moreover, we uncovered a decrease of muscular mass index and grip test in the reduced exercise capacity group (p = 0.001 and p = 0.047 respectively), whilst 38.9% of patients with low exercise capacity had a sarcopenia, compared to 10.9% in those with normal exercise capacity (p = 0.001). Myocardial function was normal with similar systolic and diastolic parameters between groups whilst reduced exercise capacity was associated with a slightly shorter pulmonary acceleration time, despite no pulmonary hypertension.

Conclusion: Three months after a severe COVID-19 pulmonary infection, more than one third of patients had an impairment of exercise capacity which was associated with a reduced pulmonary function, a reduced skeletal muscle mass and function but without any significant impairment in cardiac function.

*Correspondence: Laurent.boyer@aphp.fr
†Bruno Ribeiro Baptista and Thomas d’Humières contributed equally to this work
1 Université Paris Est Créteil (UPEC), FHU SENEC, IMRB, INSERM, Créteil, France
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Keywords: SARS-CoV-2, COVID-19, Cardiopulmonary exercise testing, Pulmonary function, Skeletal muscle, Sarcopenia

Background
The pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents the greatest global public health crisis of the last decades. Most of the knowledge about COVID-19, including its clinical manifestations and early evolution comes from studies focusing on the acute infection phase [1, 2] or short-term convalescence phase [3]. Whilst pulmonary sequelae have been extensively analyzed, few studies focused on factors contributing to impaired exercise capacity.

Indeed, pulmonary alteration such as reduction of diffusing capacity and restrictive pattern have been reported in up to one third of COVID-19 survivors, as previously described in other coronavirus pneumonia such as severe acute respiratory syndrome (SARS) or middle east respiratory syndrome (MERS) [4–9]. Recently, exercise capacity limitation has also emerged as a frequent complication leading to long-term disability in the context of COVID-19 infection [10, 11]. The diagnosis of altered exercise capacity and the understanding of the underlying factors are crucial for patients since they may benefit early from a personalized rehabilitation program. Clinical symptoms and 6-min walk test (6-MWT) may fail to detect such a reduced exercise capacity, whilst cardiopulmonary exercise test (CPET) may unmask exercise limitation.

To decipher the mechanisms underlying the exercise capacity limitation, we conducted a comprehensive prospective evaluation in severe COVID-19 pulmonary infection survivors 3 months after hospital discharge in COVulnerability cohort. More specifically, we performed in addition to CPET and 6-MWT, lung function test, echocardiography, skeletal muscle mass and function evaluation, and measured circulatory inflammatory biomarkers.

Methods
Study design and participant
COVulnerability is an ongoing prospective monocentric study, conducted at Henri Mondor Hospital, APHP, Créteil, France. Patient were included between March 2020 and July 2021 when diagnosed with severe COVID-19 pulmonary infection [12], confirmed by positive polymerase chain reaction or serology, hospitalized at intensive care unit (ICU) or at conventional care unit for more than 7 days and with oxygen therapy during hospitalization (>3 l/min). As part of routine clinical care, a follow-up visit was scheduled 3 months after hospital discharge for a comprehensive evaluation. Patients were excluded if they were under 18 years old or pregnant. The study was approved as part of routine clinical care by ethical committee Comité consultatif sur le traitement de l’information en matière de recherche (C.C.T.I.R.S.) of the Henri Mondor Hospital. An agreement was obtained from patients prior to CPET, pulmonary function tests and echocardiography at rest.

Demographics, clinical and laboratory findings upon hospital admission, during hospital stay and 3 months post hospital discharge were collected including medical history before COVID-19 infection, smoking status (pack-years), body mass index (BMI) and severity of the acute COVID-19 infection (use of high-flow nasal cannula (HFNC), invasive mechanical ventilation, extracorporeal membrane oxygenation (ECMO)). Assessment of COVID-19-related long-term organ damage was evaluated and included lung function at rest, exercise testing with VO2peak measurement, transthoracic echocardiography at rest. Skeletal muscle testing (grip and pinch test) was assessed using a standard handgrip echocardiography at rest. Appendicular skeletal muscle mass (ASMM) was determined using dual-energy X-ray absorptiometry ( Lunar iDXA, GE Healthcare, UK) as the fat-free soft-tissue masses of the arms and legs divided by height squared [13] and ASMM index (ASMMI) was then computed as ASMM divided by height squared. The cutoff for defining sarcopenia was two standard deviations below the mean sex-specific ASMMI values in the Rosetta Study (5.45 for females and 7.26 for males), as proposed by Baumgartner et al. [13]. Biological analysis included kidney evaluation by creatinine concentrations and inflammatory evaluation (C reactive protein (CRP), IL6, IL8, TNF).

Cardiopulmonary test exercise protocol
The instructions given to the subjects were the routine instructions sent to patients coming to the laboratory for clinical exercise testing [14]. Symptom-limited CPET was performed using an electronically braked cycle ergometer (Jaeger Vyntus CPX), under the supervision of a physician with defined criteria for stopping, such as serious cardiac arrhythmias, hypotension, electrocardiographic changes (ST-segment and T-wave changes, arrhythmias). An incremental exercise protocol was used, in which the work rate was increased by 10 W to 20 W min−1 after an initial 2 min of unloaded cycle. Standard 12-lead...
exercise capacity, i.e. \( \text{V} \text{O}_2 \text{peak} \) ≥ 30 s. Patients were divided in two groups: (1) normal gas exchange ratio, minute ventilation (\( \text{V'\text{E}}; \text{L/min} \)), respiratory rate, the ventilatory equivalent for carbon dioxide (\( \text{V'E/V'CO}_2 \)) was determined and averaged every 30 s. Patients were divided in two groups: (1) normal exercise capacity, i.e. \( \text{V} \text{O}_2 \text{peak} \geq 80\% \) of predicted values and (2) reduced exercise capacity, i.e. \( \text{V} \text{O}_2 \text{peak} < 80\% \) of predicted values.

**Pulmonary function testing**

Each participant underwent spirometry, plethysmography, and DL\(_{\text{CO}}\) according to ATS/ERS consensus guidelines [15]. DL\(_{\text{CO}}\) was measured using the single breath method. K\(_{\text{CO}}\), which is DL\(_{\text{CO}}\) corrected for alveolar volume, was used for the analysis. DL\(_{\text{CO}}\) and K\(_{\text{CO}}\) were corrected for hemoglobin. The spirometry, lung volumes and DL\(_{\text{CO}}\) measurements were expressed as percentage of predicted normal values using reference values taken from the prediction equations of the GLI 2012 [16].

**Transthoracic echocardiography at rest**

Patients underwent transthoracic echocardiography using Vivid E95 ultrasound system (General Electric). Left ventricular (LV) and left atrial (LA) volumes were measured in two-dimensional apical views according to the biplane Simpson rule. Left ventricular function was assessed using LV ejection fraction (LVEF, biplane Simpson method) and global longitudinal strain (GLS). Mitral inflow velocity pattern, peak velocities of E and A waves and E wave deceleration time were recorded as recommended [17]. Mitral lateral E’ velocities were measured by tissue Doppler imaging. Systolic pulmonary arterial pressure (calculated from tricuspid regurgitation flow) and pulmonary acceleration time (PacT) was acquired using Doppler method. Right ventricular (RV) size was assessed by RV basal and mid dimensions and diastolic surface and RV function by Tricuspid Annular Plane Systolic Excursion (TAPSE), S’ wave velocity (Doppler tissue imaging), RV ejection delays (RVEDs) and tricuspid regurgitation velocity (TRV) as previously published[18].

**Data presentation and statistical analysis**

Continuous variables are reported as mean ± standard deviation (SD) and compared using the unpaired Student t test or the Mann–Whitney test, as appropriate. Qualitative variables are expressed as numbers and percentages and compared with the Chi\(^2\) or Fischer tests, as appropriate. Pearson correlation coefficients were computed for continuous-continuous variables correlations. Univariable and multivariable linear regression models were used to assess the relationship between VO\(_2\)peak and variables of interests, using a stepwise backward approach for multivariable analysis by first entering all covariates associated with VO\(_2\)peak at the p < 0.2 level in univariate analysis and then removing not significant factors at the p < 0.05 level until the final model was reached. All analyses were performed at the two-tailed P < 0.05 level, using Stata v16.1 (StataCorp, College Station, TX, USA).

**Results**

Among the 220 survivors for COVID-19 severe acute pulmonary infection included in COVulnerability cohort, 105 agreed to benefit from a follow-up evaluation three months after hospital discharge. The mean age of patients was 59.2 years and 79 (75.2%) were male. The most common comorbidity was hypertension (41.9%), followed by diabetes (27.6%), and dyslipidemia (20%). Forty-five patients (43.3%) had been admitted to the intensive care unit (ICU) during the acute phase. During hospitalization, 16 patients (15.7%) required high flow nasal cannula (HFNC) and 26 (25.2%) invasive mechanical ventilation (IMV). Other patient’s characteristics and clinical outcomes are shown in Table 1.

Despite no major symptoms of dyspnea and 6-MWT in normal range, more than a third of patients (37 patients, 35%) had an impaired CPET with a VO\(_2\)peak under 80%. Interestingly, patients with a reduced exercise capacity did not complain of dyspnea and had similar 6-MWT as compared with those having normal exercise capacity. Compared to patients with normal exercise capacity, patients with reduced exercise capacity were more often men (89.2% vs. 67.6%, \( p = 0.015 \)), with diabetes (45.9% vs. 17.6%, \( p = 0.002 \)), renal dysfunction (21.6% vs. 17.6%, \( p = 0.006 \)) and lower BMI (25.79 ± 3.68 vs. 29.07 ± 5.24, \( p = 0.001 \)). Of note, smoking habits was similar between groups. The severity of acute COVID-19 disease was not different between groups in terms of ICU admission, HFNC, IMV and ECMO (Table 1). During the exercise test, patients with altered exercise capacity compared to the others reached a lower maximal work, a lower maximal heart rate and had a higher breathing reserve (Table 2). We do not observe desaturation between groups, at the peak of exercise the saturation was 98.4 ± 3.2% in the normal group vs. 99 ± 1.42% in the impaired group (\( p = 0.239 \)).

Reduced exercise capacity was associated with a significant decrease in respiratory function at rest: compared to the normal exercise capacity group, predicted FVC was significantly lower in the impaired
Table 1  Patient’s characteristics and comparison of clinical factors between patients with a normal and reduced exercise capacity

| Parameters | All patients (n = 105) | Normal exercise capacity (n = 68) | Reduced exercise capacity (n = 37) | p-Value |
|------------|------------------------|----------------------------------|-----------------------------------|---------|
| Age, years | 59.21 ± 11.81          | 59.68 ± 12.16                    | 58.35 ± 11.26                    | 0.585   |
| Male (%)   | 79 (75.2)              | 46 (67.6)                        | 33 (89.2)                        | 0.015   |
| BMI before COVID-19, kg/m² | 29.11 ± 5.51  | 30.29 ± 5.64                    | 27.16 ± 4.74                    | 0.009   |
| BMI, kg/m² | 27.92 ± 4.98           | 29.07 ± 5.24                     | 25.79 ± 3.68                     | 0.001   |
| Change in BMI before-after COVID-19, kg/m² | −1.16 ± 1.93 | −0.90 ± 1.59                   | −1.59 ± 2.35                   | 0.105   |
| Tobacco history (%) | 48 (45.7)  | 34 (50)                          | 14 (37.8)                       | 0.232   |
| Smoking, pack-years | 11.69 ± 16.29 | 11.5 ± 15.22                    | 12.06 ± 18.38                   | 0.874   |
| mMRC dyspnea scale (0/ 1/ 2/ 3/ 4) | 67/ 31/ 5/ 2/ 0 | 66/ 21/ 1/ 0/ 0                  | 24/ 12/ 1/ 0/ 0                  | 0.61    |
| Comorbidities |                     |                                  |                                  |         |
| Hypertension (%) | 44 (41.9)  | 25 (36.8)                        | 19 (51.4)                       | 0.148   |
| Diabetes (%) | 29 (27.6)              | 12 (17.6)                        | 17 (45.9)                       | 0.002   |
| Dyslipidemia (%) | 21 (20)  | 13 (19.1)                        | 8 (21.6)                        | 0.759   |
| Ischemic cardiomyopathy (%) | 17 (16.2) | 12 (17.6)                        | 5 (13.5)                        | 0.583   |
| Obstructive sleep apnea (%) | 15 (14.3) | 8 (11.8)                         | 7 (18.9)                        | 0.317   |
| Malignancy (%) | 14 (13.5) | 8 (11.9)                         | 6 (16.2)                        | 0.541   |
| Chronic kidney disease (%) | 11 (10.5) | 3 (4.4)                          | 8 (21.6)                        | 0.006   |
| COPD (%) | 1 (1)                  | 1 (1.5)                          | 0 (0)                           | 0.459   |
| During COVID-19 hospitalisation |             |                                  |                                  |         |
| ICU stay (%) | 45 (43.3)  | 26 (38.8)                        | 19 (51.4)                       | 0.216   |
| HFNC (%) | 16 (15.7)              | 10 (15.2)                        | 6 (16.7)                        | 0.841   |
| IMV (%) | 26 (25.2)              | 14 (21.2)                        | 12 (32.4)                       | 0.209   |
| Tracheotomy (%) | 2 (1.9)  | 1 (1.5)                          | 1 (2.7)                         | 0.675   |
| ECMO (%) | 4 (3.9)                | 1 (1.5)                          | 3 (8.1)                         | 0.097   |
| Pulmonary embolism (%) | 8 (7.8)  | 7 (10.6)                         | 1 (2.7)                         | 0.150   |
| Acute kidney injury (%) | 23 (22.1) | 11 (16.2)                        | 12 (33.3)                       | 0.045   |
| Cardiogenic shock (%) | 2 (1.9)  | 2 (3)                            | 0 (0)                           | 0.289   |

Data are presented as n, n (%) or mean ± SD. Bold type represents statistical significance. BMI, Body mass index; mMRC, modified Medical Research Council; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IMV, invasive mechanical ventilation; HFNC, high-flow nasal cannula; ECMO, extracorporeal membrane oxygenation.

As predicted FEV1 (76.76 ± 17.92% vs. 93.26 ± 16.38%, p < 0.0001) and TLC (75.81 ± 13.24% vs. 87.88 ± 13.79%, p < 0.0001), DLCO was also significantly lower in the reduced exercise capacity group (65.14 ± 15.53% vs. 74.66 ± 20.28%, p = 0.015). KCO was not modified in the reduced exercise capacity group, highlighting a restrictive pulmonary pattern in patients presenting an altered exercise capacity (Table 2).

Furthermore, we found a reduced skeletal muscle mass by ASMMI in the altered exercise capacity group (7.36 ± 0.94 kg/m² vs. 7.85 ± 1.17 kg/m², p = 0.001) together with a decrease in grip test (31.50 ± 9.27 vs. 36.33 ± 10.71, p = 0.047) highlighting an impairment in skeletal muscle strength (Table 2). There also was a decrease in VO₂/kg of muscle leg in the reduced exercise capacity (68.5 ± 16 vs. 95.7 ± 18.5, p < 0.0001). Notably, sarcopenia was more frequent among low exercise capacity patients compared to the others: 38.9% vs 10.9%, (p = 0.001).

We did not observe any significant cardiac dysfunction with systolic and diastolic parameters in normal range values at rest. Furthermore, LVEF and right ventricular function were similar in both groups (Table 2). Reduced exercise capacity was associated with a shorter PAcT (107 ± 27 ms vs. 126 ± 26 ms, p = 0.02) despite no argument for pulmonary hypertension (based on tricuspid regurgitation peak velocity). Predicted VO₂/Heart rate was decreased in the altered exercise capacity group (66.03 ± 9.58% vs. 96.62 ± 14.69%, p < 0.0001).

As expected, the univariate analysis showed correlation between VO₂peak and the predicted values of FEV1, FVC, TLC, DLCO but not with KCO (Table 3, see Additional file 1). Notably, VO₂peak was also correlated with skeletal muscle mass and grip test. In addition, VO₂peak...
Table 2  Comparison of pulmonary function, skeletal muscle parameter and transthoracic echocardiography between patients with a normal and reduced exercise capacity

| Parameters                                      | All patients (n = 105) | Normal exercise capacity (n = 68) | Reduced exercise capacity (n = 37) | p-Value       |
|-------------------------------------------------|------------------------|-----------------------------------|-----------------------------------|---------------|
| Exercise capacity assessment (CPET)             |                        |                                   |                                   |               |
| Wmax, W (ml/min/kg)                             | 116.14 ± 51.67         | 130.74 ± 53.39                   | 89.32 ± 35.55                    | 0.0002        |
| HRmax, bpm                                      | 139.43 ± 25.80         | 143.51 ± 26.38                   | 131.92 ± 23.21                   | 0.013         |
| Breathing reserve, %                             | 25.49 ± 19.13          | 21.14 ± 18.38                    | 33.14 ± 18.23                    | 0.009         |
| VO2max, ml/min                                  | 1523.89 ± 552.69       | 1718.90 ± 540.20                 | 1165.49 ± 368.13                 | <0.0001       |
| VCO2max, ml/min                                 | 1764.03 ± 696.62       | 1991.90 ± 700.66                 | 1345.24 ± 458.19                 | <0.0001       |
| RER                                             | 1.15 ± 0.11            | 1.15 ± 0.09                      | 1.15 ± 0.13                      | 0.979         |
| VO2max/BW, ml/min kg                            | 18.28 ± 5.34           | 20.15 ± 5.16                     | 14.84 ± 3.75                     | <0.0001       |
| VO2max/kg leg muscle mass (ml/kg leg/min)       | 86.4 ± 21.8            | 95.7 ± 18.5                      | 68.5 ± 16                        | <0.0001       |
| Anaerobic threshold %VO2 max predicted          | 62.7 ± 19.8            | 71.1 ± 17.4                      | 45.96 ± 12.2                     | <0.0001       |
| Respiratory frequency, breathe/min              | 38.98 ± 8.87           | 39.76 ± 8.56                     | 37.55 ± 9.36                     | 0.319         |
| VO2/HR, ml/beat                                 | 11.12 ± 3.30           | 12.18 ± 3.27                     | 9.02 ± 2.17                      | <0.0001       |
| VO2/HR, % predicted                             | 86.32 ± 19.59          | 96.62 ± 14.69                    | 66.03 ± 9.58                     | <0.0001       |
| Hemoglobin, g/dl                                | 13.57 ± 1.54           | 13.99 ± 1.39                     | 12.77 ± 1.52                     | <0.0001       |
| 6-min walking distance, m                       | 485.18 ± 111.08        | 494.02 ± 109.47                  | 469.22 ± 113.72                   | 0.285         |
| Pulmonary function                              |                        |                                   |                                   |               |
| FVC, L                                          | 3.49 ± 1.11            | 3.67 ± 1.18                      | 3.17 ± 0.88                      | 0.026         |
| FVC, % predicted                                | 84.90 ± 18.08          | 90.54 ± 16.69                    | 74.54 ± 15.99                    | <0.0001       |
| FEV1, L                                         | 2.78 ± 0.82            | 2.91 ± 0.83                      | 2.55 ± 0.76                      | 0.030         |
| FEV1, % predicted                               | 87.45 ± 18.62          | 93.26 ± 16.38                    | 76.76 ± 17.92                    | <0.0001       |
| FEV1/FVC (%)                                    | 80 ± 7                 | 81 ± 8                           | 80 ± 7                           | 0.828         |
| TLC, L                                          | 5.42 ± 1.24            | 5.57 ± 1.35                      | 5.13 ± 0.93                      | 0.081         |
| TLC, % predicted                                | 83.70 ± 14.72          | 87.88 ± 13.79                    | 75.81 ± 13.24                    | <0.0001       |
| DLCO, % predicted                               | 71.27 ± 19.34          | 74.66 ± 20.48                    | 65.14 ± 15.53                    | 0.015         |
| KCO, %                                          | 93.87 ± 17.56          | 94.79 ± 17.59                    | 92.19 ± 17.62                    | 0.472         |
| PaO2, mmHg                                      | 89.04 ± 9.35           | 87.82 ± 9.68                     | 90.81 ± 8.7                      | 0.173         |
| PaCO2, mmHg                                     | 37.08 ± 4.97           | 37.21 ± 2.5                      | 36.84 ± 7.24                     | 0.73          |
| Skeletal muscle mass and function               |                        |                                   |                                   |               |
| ASMMI, kg/m²                                     | 7.85 ± 1.17           | 8.13 ± 1.19                      | 7.36 ± 0.94                      | 0.001         |
| Sarcopenia (%)                                   | 21 (21)                | 7 (10.9)                         | 14 (38.9)                        | 0.001         |
| Grip test, kg                                   | 34.42 ± 10.37          | 36.33 ± 10.71                    | 31.5 ± 9.27                      | 0.047         |
| Pinch test, kg                                   | 6.60 ± 2.17            | 7.04 ± 2.31                      | 6.07 ± 1.82                      | 0.054         |
| Transthoracic echocardiography                  |                        |                                   |                                   |               |
| CO L/min                                        | 5.71 ± 1.37            | 5.88 ± 1.44                      | 5.44 ± 1.24                      | 0.182         |
| LVMi, g/m2                                       | 84.43 ± 24.5           | 79.31 ± 18.01                    | 93.43 ± 31.34                    | 0.012         |
| LVEF (2D), %                                    | 60.25 ± 6.06           | 60.31 ± 5.75                     | 60.13 ± 6.64                     | 0.898         |
| Global longitudinal strain, %                   | −17.24 ± 2.45          | −17.59 ± 2.39                    | −16.66 ± 2.49                    | 0.114         |
| E/A ratio                                       | 0.89 ± 0.33            | 0.90 ± 0.34                      | 0.88 ± 0.32                      | 0.767         |
| E/E ratio                                       | 7.1 ± 2.20             | 7.10 ± 2.03                      | 7.12 ± 2.56                      | 0.971         |
| E’ lateral, cm/s                                | 9.46 ± 3.07            | 9.54 ± 3.36                      | 9.29 ± 2.44                      | 0.733         |
| LAVi, mL                                        | 28.15 ± 9.78           | 27.82 ± 8.77                     | 28.70 ± 11.39                    | 0.697         |
| RVEDs, cm²                                      | 17.43 ± 4.45           | 16.70 ± 4.34                     | 18.65 ± 4.45                     | 0.077         |
| TAPSE, mm                                       | 21.49 ± 3.33           | 21.74 ± 3.47                     | 21.04 ± 3.05                     | 0.389         |
| S’ wave, cm/s                                   | 12.79 ± 2.08           | 12.72 ± 2.01                     | 12.95 ± 2.26                     | 0.663         |
| TRV, m/s                                        | 2.32 ± 0.34            | 2.30 ± 0.32                      | 2.35 ± 0.37                      | 0.656         |
| systolic PAP, mmHg                               | 25 ± 6.05              | 24.61 ± 5.65                     | 25.3 ± 6.66                      | 0.646         |
| PACT, ms                                        | 119.7 ± 27.53          | 125.84 ± 25.95                   | 106.66 ± 27                      | 0.024         |
| RA area, cm²                                     | 14.68 ± 4.42           | 14.35 ± 4.42                     | 15.30 ± 4.44                     | 0.387         |
was correlated with left ventricle mass index, GLS, E/E’ ratio, RVEDs, TRV and PacT (Table 3, see Additional file 1). Interestingly, in multivariable analysis, age, sex, predicted TLC, ASMMI, GLS and E/E’ ratio, showed an independent correlation with VO2peak (Table 3).

Finally, we identified a slight but statistically significant increase in circulatory inflammatory biomarkers (CRP, IL6, TNFα) in patients with reduced VO2peak compared to normal exercise capacity group (Table 4). There was a negative correlation between VO2peak and IL6 (r = −0.24, p = 0.013), TNFα (r = −0.34, p = 0.0003) and CRP (r = −0.29, p = 0.003).

**Discussion**

Three months after hospitalization for a severe COVID-19 pulmonary infection, we show that 35% of survivors of COVulnerability cohort have a clinically occult impaired exercise capacity, which was unmasked by CPET whereas clinical symptoms and 6-MWT were not contributive. Beyond alteration of pulmonary function, exercise limitation was associated to sarcopenia

**Table 3** Multivariable analysis to identify the factors associated with VO2peak

| Parameters | Unadjusted analyses | Multivariable analysis |
|------------|---------------------|------------------------|
|            | Unadjusted linear regression coefficient (CI95%) | p-Value | Adjusted linear regression coefficient (CI95%) | p-Value |
| Age, years | 0.18 0.004 (0.000;0.008) | 0.070 | 0.01 (0.003–0.012) | 0.001 |
| Body mass index, kg/m² | 0.33 0.016 (0.007;0.025) | 0.0006 | (-) |
| Pulmonary function | | | | |
| FVC, % predicted | 0.52 0.007 (0.005;0.009) | 0.0001 | (-) |
| FEV1, % predicted | 0.51 0.014 (0.005;0.009) | 0.0001 | (-) |
| TLC, % predicted | 0.52 0.009 (0.006;0.012) | 0.0004 | 0.01 (0.003–0.001) | 0.0004 |
| DLCO, % predicted | 0.38 0.005 (0.003;0.007) | 0.0001 | (-) |
| Skeletal muscle mass and function | | | | |
| ASMMI, kg/m² | 0.34 0.072 (0.032;0.113) | 0.0006 | 0.009 (0.05–0.12) | <0.0001 |
| Grip test, kg | 0.25 0.006 (0.001;0.011) | 0.027 | (-) |
| Transthoracic echocardiography | | | | |
| LVMI, g/m² | -0.29 -0.003 (-0.005;−0.001) | 0.009 | (-) |
| PacT, ms | 0.35 0.003 (0.000;0.005) | 0.017 | (-) |

**Table 4** Comparison of circulatory inflammatory biomarkers between patients with normal and reduced exercise capacity

| Parameters (normal values) | All patients (n = 105) | Normal exercise capacity (n = 68) | Reduced exercise capacity (n = 37) | p-Value |
|----------------------------|------------------------|----------------------------------|----------------------------------|---------|
| CRP, mg/L (< 5 mg/l) | 3.61 ± 0.00 | 2.46 ± 0.26 | 5.79 ± 0.79 | 0.012 |
| Interleukin-6, pg/ml (< 7 pg/l) | 5.80 ± 7.58 | 5.17 ± 7.21 | 6.96 ± 8.18 | 0.013 |
| Interleukin-8, pg/ml (6.7–16.2 pg/ml) | 116.03 ± 249.6 | 131.24 ± 299.17 | 88.06 ± 110.27 | 0.085 |
| TNFα pg/ml (4.05–8.34 pg/ml) | 19.36 ± 8.87 | 17.3 ± 7.82 | 23.14 ± 9.51 | <0.0001 |

Data are presented as mean ± SD. Bold type represents statistical significance. CRP C reactive protein, TNFα tumor necrosis factor α
and reduced skeletal muscle function but no significant cardiac dysfunction.

Our results highlight the importance to perform a global and systematic evaluation of severe patients during follow up, including CPET to detect exercise limitation beyond the existence of lung sequelae. Indeed, the initial disease severity during the acute hospitalization was not related to the exercise capacity at 3 months, highlighting the complexity to predict which patient will develop an exercise limitation. Furthermore, CPET is able to unmask an exercise limitation that cannot be identified by dyspnea measure or 6-MWT [19]. In line with this observation, we showed that these two latter criteria were similar between normal and impaired exercise capacity groups and were not contributive for the diagnosis of exercise limitation. Thus, our study adds a piece of evidence for the high rate of exercise limitation in COVID-19 survivors as previously reported in coronavirus outbreak [4, 20, 21] and more recently identified in COVID-19 patients [10, 11, 22].

Once raising awareness of exercise limitation in the follow-up of COVID-19 patients, we aimed to decipher the underlying mechanisms by performing a comprehensive multi-organ evaluation to identify factors associated with a reduced exercise capacity. Whilst most of studies are focusing on lung alterations [11, 22], our study is the first to identify sarcopenia as a main contributor. Indeed, a reduced exercise capacity was associated with a decrease in muscle mass and function assessed by ASMMI and grip test. The reduction of VO2/kg leg muscle mass in the group with a reduced exercise capacity suggest strongly that the muscle is dysfunctional. The reduction of anaerobic threshold is also an argument for an alteration of muscle function responsible of the exercise limitation. Moreover, sarcopenia was very common among patients with low exercise capacity, thus clarifying the suspicion of muscular deconditioning reported by previous studies [11]. Such a link between exercise limitation and sarcopenia has been reported in chronic cardiac and lung diseases [23, 24]. However, in our cohort, COVID-19 survivors with an exercise limitation had a higher rate of sarcopenia (almost 40%) compared with these diseases (15–34%) [25–27] highlighting the important chronic impact of COVID-19 on muscle mass. Based on these results, prevention and treatment of sarcopenia must be considered during follow up of COVID-19 survivors.

If obesity and high BMI are clearly associated with higher frequency of severe COVID-19 infections and worse prognosis in the acute phase [28, 29], we showed that patients with low BMI may be more vulnerable in the follow-up phase with a lower exercise capacity. We also found that an impaired exercise capacity was associated with a lower lung function and particularly with a decrease in lung volume that characterized COVID-19 survivors [8, 9, 22, 30, 31]. A reduction of gas transfer measured by DLCO was also present, but this difference disappeared when this value was related with alveolar ventilation (KCO), confirming the restrictive pulmonary pattern in patients presenting a decreased effort capacity. However, the breathing reserve at VO2peak was higher in the reduced exercise group suggesting that this restrictive profile is not responsible of the exercise limitation.

Echocardiography at rest suggest that the role of cardiac dysfunction can be ruled out regarding the lack of systolic and diastolic function abnormalities and the weak correlation between systolic and diastolic parameters with VO2peak. However, we cannot exclude a cardiac dysfunction during exercise based on VO2/heart rate in patients with impaired exercise capacity. Another explanation to the VO2/heart reduction could be the reduction of peripheral extraction associated with muscle dysfunction. Further explorations such effort cardiac echography would be interested to determine the impact of cardiac dysfunction, but it was not in the scope of this study.

We also observed that inflammatory circulating biomarkers are higher in patients with low exercise capacity. That could be an important component of the phenotype of patients with low exercise capacity associated with altered lung function and muscle alteration. Lower muscle mass may be related to persistent systemic inflammation from acute COVID-19 infection [32, 33] to chronic sequelae [30]. Indeed, a high level of circulating inflammatory biomarkers, related to a chronic inflammation, is known to be associated with lower skeletal muscle strength and muscle mass [34, 35] and can participate to the deconditioning process observed in our patients. The higher level of IL-6 and TNFα in the reduced exercise capacity group at 3 months of the acute disease highlight a persistent inflammatory signature. These results are consistent with the IL-6 and TNFα serum levels that are described to be independent and significant predictors of COVID-19 disease severity [36]. Decrease in hemoglobin level in the reduced exercise capacity group can be linked to this persistent inflammation.

One limitation of our study includes the absence of preexisting evaluation of these patients before the acute phase of the disease and organ alteration that may precede the hospitalization. For example, sarcopenia could be induced by diabetes prior to COVID-19 infection. BMI values before COVID-19 infection showed a difference between groups, it can limit the interpretation and
allow to hypothesize that other parameters, like a preexisting muscle mass and function alteration, was already present between groups.

**Conclusion**

At 3 months of a severe COVID-19 pulmonary infection, one third of patients enrolled in COVulnerability cohort have an exercise limitation. This limitation is associated with a lung and muscular dysfunction. Adapted rehabilitation for these patients could decrease the global sequelae of this disease.

**Abbreviations**

6-MWT: 6-Minute walk test; ASMMI: Appendicular skeletal muscle mass index; BMI: Body-mass index; CO: Cardiac output; COVID-19: Coronavirus disease 2019; CPET: Cardiopulmonary exercise testing; DLCO: Diffusing capacity of the lungs for carbon monoxide; ECMO: Extracorporeal membrane oxygenation; FEV1: Forced expiratory volume in the first second; FVC: Forced vital capacity; GLS: Global longitudinal strain; HFNC: High-flow nasal cannula; HRmax: Maximum heart rate; ICU: Intensive care unit; IMV: Invasive mechanical ventilation; KCO: Diffusion coefficient; LA: Left atrial volume index; LVEF: Left ventricular ejection fraction; LVMI: Left ventricular mass index; PaCO2: Partial pressure of carbon dioxide assessed by blood gas analysis; PaCO2: Partial pressure of carbon dioxide assessed by blood gas analysis; PAC: Pulmonary arterial oxygen saturation; PACE: Pulmonary acceleration time; PAP: Pulmonary artery pressure; RA: Right atrium; RER: Respiratory exchange ratio; RV: Right ventricle; TAPSE: Tricuspid Annular Plane Systolic Excursion; TCI: Total lung capacity; TNFα: Tumor necrosis factor α; TRV: Tricuspid regurgitation velocity; V'C02max: Maximum carbon dioxide production; VO2max: Maximum oxygen uptake; VO2max/kg: Maximum oxygen uptake per kg body weight; WRmax: Maximum work rate.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12931-022-01977-z.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

IB, FS, GJ, LEA, RC, BB, LAC, EA, SH, AM, GD, TD, LB contributed to the study design. BRB, IB, FS, GJ, LEA, MH, RC, BB, LAC, EA, SH, AM, GD, TD, LB participated in the drafting and revision of the manuscript. All authors have approved the manuscript prior to submission.

**Funding**

This study received funding from Paris-Est Créteil University (UPEC).

**Availability of data and materials**

The datasets used and/or analysed in the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The study was approved as part of routine clinical care by ethical committee Comité consultatif sur le traitement de l’information en matière de recherche (C.C.T.I.R.S.) of the Henri Mondor Hospital. An agreement was obtained from patients prior to CPET, pulmonary function tests and echocardiography at rest.

Consent for publication

Not applicable.

**Competing interests**

BRB, IB, FS, GJ, LEA, RC, BB, LAC, EA, SH, AM, GD, TD, LB have no financial or non-financial competing interests to disclose. GD reports receiving grants from Paris-Est Créteil University (UPEC).

**Author details**

1. Université Paris Est Créteil (UPEC), FHU SENEQ, IMRB, INSEM, Créteil, France.
2. Département de Physiologie-Explorations Fonctionnelles, Hôpitaux Universitaires Henri Mondor, AP-HP, Avenue Maréchal de Lattre de Tassigny, Créteil, France.
3. Unité de Pneumologie, Service de Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France.
4. Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France.
5. Département d’Hématologie et d’Immunologie Biologiques, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France.
6. Biostatistics Department, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, Créteil, France.
7. CEpiA IMRB U955, FHU SENEQ, Université Paris Est (UPEC), Créteil, France.

Received: 15 October 2021 Accepted: 6 March 2022

Published online: 22 March 2022

**References**

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
2. Chen N, Zhou M, Dong X, Qu J, Ji Y, Wang R, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.
3. Huang Y, Tan C, Wu J, Chen M, Wang Z, Luo L, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21(1):163.
4. Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60(5):401–9.
5. Ngai JC, Ko FW, Ng SS, To K-W, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010;15(3):543–50.
6. Park WB, Jun KL, Kim G, Choi JP, Rhee J-Y, Cheon S, et al. Correlation between pneumonia severity and pulmonary complications in middle east respiratory syndrome. J Korean Med Sci. 2018;33(24):e169.
7. Frija-Masson J, Debray M-P, Gilbert M, Lescure F-X, Travert F, Borie R, et al. Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection. Eur Respir J. 2020;56(2):2001754.
8. Noel-Savina E, Watge T, Faviez G, Lepage B, Mhanna LT, Pontier S, et al. Severe SARS-CoV-2 pneumonia: clinical, functional and imaging outcomes at 4 months. Respir Med Res. 2021;80:100822.
9. Wu X, Liu Y, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-Month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9(7):747–54.
10. Skjørtøn I, Ankerstjerne OAW, Trebinjac D, Brønstad E, Rasch-Halvorsen Ø, Einvik G, et al. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. Eur Respir J. 2021;58(2):2100996.
11. Rinaldo RF, Mondoni M, Parazzini EM, Pitari F, Brambilla E, Luraschi S, et al. Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors. Eur Respir J. 2021;58(2):2100870.
12. Gandhi RT, Lynch JB, del Rio C. Mild or moderate COVID-19. N Engl J Med. 2020;383(18):1757–66.
13. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755–63.
14. Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. Eur Respir J. 1997;10(1):2662–89

15. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J. 1993;6(Suppl 16):5–40.

16. Quanjer PH, Staenuxe S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.

17. Nagueh SF, Abraham TP, Aurigemma GP, Bax JJ, Beladan C, Browning A, et al. Interobserver variability in applying American Society of Echocardiography/European Association of Cardiovascular Imaging 2016 guidelines for estimation of left ventricular filling pressure. Circ Cardiovasc Imaging. 2019;12(1): e008122.

18. Ernande L, Cottin V, Leroux P-Y, Girerd N, Huez S, Mulliez A, et al. Right isovolumic contraction velocity predicts survival in pulmonary hypertension. J Am Soc Echocardiogr. 2013;26(3):297–306.

19. Bai C, Chotirmall SH, Rello J, Alba GA, Ginns LC, Krishnan JA, et al. Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force. Eur Respir Rev. 2020;29(157).

20. Su M-C, Hsieh Y-T, Wang Y-H, Lin A-S, Chung Y-H, Lin M-C. exercise capacity and pulmonary function in hospital workers recovered from severe acute respiratory syndrome. Respiration. 2007;74(5):511–6.

21. Ong K-C, Ng AWK, Lee LS-U, Hui CW, Ling CYC, Cheung CM, et al. Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome. Eur Respir J. 2004;24(3):436–42.

22. Mottejunaite J, Balagny P, Arnoult F, Mangin L, Bancal C, Vidal-Petiot E, et al. Hyperventilation as one of the mechanisms of persistent dyspnea in SARS-CoV-2 survivors. Eur Respir J. 2021;58(2):2101578.

23. Haykowsky MJ, Kouba EJ, Brubaker PH, Nicklas BJ, Eggebeen J, Kitzman DW. Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol. 2014;113(7):1211–6.

24. Broxterman RM, Hoff J, Wagner PD, Richardson RS. Determinants of the diminished exercise capacity in patients with chronic obstructive pulmonary disease: looking beyond the lungs. J Physiol. 2020;598(6):400–15.

25. Curcio F, Testa G, Liguori I, Papillo M, Flocco V, Panicara V, et al. Sarcopenia and heart failure. Nutrients. 2020;12(1):211.

26. Sepulveda-Loyola W, Osadnik C, Phu S, Morita AA, Duque G, Probst VS. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2020;11(5):1164–76.

27. Boyer L, Chouaid C, Bastuji-Garin S, Marcos E, Margarit L, Le Corvoisier VS. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. Ageing Res Rev. 2020;64: 101185.

28. Caci G, Albini A, Malerba M, Noonan DM, Pochetti P, Polosa R. COVID-19 and obesity: dangerous liaisons. J Clin Med. 2020;9(8):2511.

29. Huang Y, Lu Y, Huang Y-M, Wang M, Ling W, Sui Y, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism. 2020;113: 154378.

30. Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B, et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J. 2021;57(4):2003481.

31. Torres-Castro R, Vasconcello-Castillo L, Alzina-Restoy X, Solis-Navarro L, Burgos F, Puppo H, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2021;27(4):328–37.

32. Zhu J, Pang J, Ji P, Zhong Z, Li H, Li B, et al. Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis. J Med Virol. 2021;93(1):35–7.

33. Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, et al. Association of elevated inflammatory markers and severe COVID-19: a meta-analysis. Medicine (Baltimore). 2020;99(47): e23315.

34. Tuttle CSL, Thang LAN, Maier AB. Markers of inflammation and their association with muscle strength and mass: a systematic review and meta-analysis. Ageing Res Rev. 2020;64: 101185.

35. Suyn MK, Cho EN, Chang J, Ahn CM, Kim HJ. Sarcopenia correlates with systemic inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:669–75.

36. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–43.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions